|
|
|
05.11.25 - 22:18
|
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Howard Hughes Medical Institute. In 2019, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein. He currently serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee.
“I am very pleased to welcome Bill to our board of directors,” said Ari Bousbib, chairman and CEO, IQVIA. “Bill is a world-renowned scientist and physician with deep e...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.25 - 12:06
|
IQVIA Reports Third-Quarter 2025 Results (Business Wire)
|
|
|
Revenue of $4,100 million, up 5.2 percent year-over-year
GAAP Net Income of $331 million, Adjusted EBITDA of $949 million
GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00
R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x
R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year
Operating Cash Flow of $908 million; Free Cash Flow of $772 million, up 35 percent year-over-year, representing 150 percent of Adjusted Net Income
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2025.
Third-Quarter 2025 Operating Results
Revenue for the third quarter of $4,100 million increased 5.2 percent on a reported basis and 3.9 percent at constant currency, comp...
|
|
|
|
|
|
|
|
|
07.10.25 - 08:03
|
Epsilogen Announces the Appointment of Cristina Oliva, MD, PhD as Chief Medical Officer (Business Wire)
|
|
|
Board-certified oncologist who brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research OrganizationsLONDON--(BUSINESS WIRE)--Epsilogen, the world's leading pan-isotype antibody therapeutic company for the treatment of cancer, today announces the appointment of Cristina Oliva, MD, PhD, as Chief Medical Officer. Dr. Oliva is a Board-certified oncologist and brings global experience across all stages of oncology drug development.
Dr. Oliva joins Epsilogen from BerGenBio, where she served as Chief Medical Officer from 2022. Prior to this role, Dr. Oliva was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA, where she led a cross-functional team of oncology subject matter experts and established and led the IQVIA Oncology Global Scientific Advisory Board. Dr. Oliva has also held senior positions, leading oncology development programs, at Nordic Nanovector, Takeda Pharmaceuticals, GSK and Eli Lilly.
Tim Wilson, CE...
|
|
|
|
|
02.10.25 - 02:03
|
Blue Matter stellt mit Eva Kersey einen neuen Partner ein und baut damit seine Kompetenzen in Europa weiter aus (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Blue Matter freut sich mitteilen zu können, Eva Kersey als Partner mit Sitz in London für das Unternehmen gewonnen zu haben. Eva ist dem Team von Blue Matter am 16. September offiziell beigetreten und bringt umfangreiche Erfahrungen in der strategischen Beratung von Kunden aus den Bereichen Pharmazie, Biotechnologie und Medizintechnik mit.
Eva ist seit 2007 für Kunden aus dem Bereich Life Sciences tätig. Sie startete ihre Beraterkarriere bei PHP (jetzt Teil von Accenture). Seitdem bekleidete sie Führungs- und Partnerpositionen bei IMS Consulting, IQVIA und ClearView Healthcare Partners. Über die Jahre konnte sie Beratungserfahrung entlang der gesamten Wertschöpfungskette sammeln, wobei ihr Schwerpunkt auf der Entwicklung funktionsübergreifender Strategien lag. Sie hat sich vor allem auf Therapie- und Franchise-Strategien, Portfoliooptimierung sowie Preis-, Zugangs- und Evidenzstrategien spezialisiert. Außerdem verfügt sie über umfassende Expertise in allen Aspekten der ...
|
|
|
01.10.25 - 15:06
|
Blue Matter Hires New Partner, Eva Kersey, Further Strengthening Capabilities in Europe (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Blue Matter is pleased to announce that Eva Kersey has joined the firm as a Partner based in London. Eva officially joined the Blue Matter team on September 16, bringing a broad base of strategic consulting experience across pharmaceutical, biotech, and medical technology clients.
Eva has been serving life science clients since 2007. She began her consulting career at PHP (now a part of Accenture). Since then, she has served in leadership and Partner-level positions at IMS Consulting, IQVIA, and ClearView Healthcare Partners. Over the years, her consulting experience has spanned the full value chain, focusing on cross-functional strategy development. She brings a particular specialization in therapy and franchise strategy, portfolio optimization, and pricing, access and evidence strategy. She also brings significant expertise in all aspects of commercial strategy development for clinical-stage, pre-launch assets.
“I'm extremely excited to join the Blue Matter team,” Eva said....
|
|
|
30.09.25 - 22:18
|
IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique p...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
